Conference Description

SORRY! This Conference is Full. No Space Available.

September 9, 2006 Westin Diplomat Resort & Spa 3555 South Ocean Drive Hollywood, Florida Tell a friend about this conference Download the brochure for this conference See how attendees evaluated this conference CME Credits 6.6* Nonrefundable registration fee: $0. Target Audience: Rheumatologists Learning Objectives: The intimate setting of this conference will maximize learning and discussion and will enable rheumatologists to learn first hand from thought leaders in their field. Among the proposed topics and objectives will be to: discuss research findings regarding osteonecrosis of the jaw compare the safety and efficacy of intra-articular hyaluronan for the osteoarthritis treatment paradigm discuss the advantages and disadvantages in the use of the Cox-2 anti-inflammatory drug versus the traditionals in treating osteoarthritis discuss new concepts in the evaluation and management of the anti-phospholipid syndrome describe current status of a new therapy for treatment of gout explain the safety and efficacy of biologic agents in RA with an emphasis on B cell and T cell therapy Agenda: Saturday, September 9, 2006 7:45-8:30    Registration and Continental Breakfast Welcome—Charles Kahn, MD and Wayne Riskin, MD 8:30-9:20    What Do We Tell Our Patients Taking Bisphophonates Regarding Osteonecrosis of the Jaw? Michael McClung, MD 9:20-10:10    At Last! A disease modifying treatment for psoriatic arthritis Alan Brown, MD 10:10-10:30    Morning Break 10:30-11:20    Abatacept: When and why? Carlos J. Lozada, M.D., FACP, FACR 11:20-12:10    Intra-articular Hyaluronan: Evidence, controversies, and product comparisons Edward Miller, MD 12:10-1:10    Lunch 1:10-2:00    Anti-Phospholipid Syndrome: Current thinking on evaluation and management Robert Lahita, MD 2:00-2:50    B-Cell Therapy: Another option for second line therapy in the rheumatic diseases Marc Cohen, MD 2:50-3:10    Afternoon Break 3:10-4:00    Update on a Novel Therapy for Treatment of Gouty Arthritis Marc Cohen, MD 4:00-4:50    Treatment of Osteoarthritis: Challenges, myths and realities Lee Simon, MD 4:50-5:00    Closing Remarks Charles Kahn, MD and Wayne Riskin, MD Faculty: Alan Brown, MD Associate Professor of Medicine Division of Rheumatology and Immunology Vice Chairman for Education, Department of Medicine Medical University of South Carolina Marc Cohen, MD Professor of Medicine Mayo Medical School Chairman of Division of Rheumatology Mayo Clinic Jacksonville Robert G. Lahita, MD, PhD Vice-President and Chairman of Medicine Jersey City Medical Center Professor of Medicine, Mount Sinai Medical School Carlos J. Lozada, M.D., FACP, FACR Associate Professor Department of Medicine Division of Rheumatology University of Miami Miller School of Medicine Michael McClung Associate Professor of Medicine Oregon Health Sciences University Director, Oregon Osteoporosis Center Edward Miller, MD Emeritus Professor of Orthopaedic Surgery University of Cincinnati Medical Center Lee Simon, MD Associate Clinical Professor of Medicine Harvard Medical School Beth Israel Deaconess Medical Center Program Planning Committee: Charles Kahn, MD, FACP, FACR Wayne G. Riskin, MD, FACP, FACR Elaine Kahn, MSN, ARNP *Continuing Education Information This activity has been planned and implemented in accordance with the Essentials and Standards of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Massachusetts Medical School (UMMS) and the National Association for Continuing Education. UMMS is accredited by ACCME to provide continuing medical education for physicians. UMMS designates this continuing medical education activity for 6.6 credit hours in Category I toward the Physicians Recognition Award of the American Medical Association. Each physician should claim only those hours of credit that he/she actually spent in the educational activity. Under the auspices of the University of Massachusetts Medical School Office of Continuing Education this offering meets the requirements for 8.0 contact hours, as specified by the Massachusetts Board of Registration in Nursing (244-CMR 5.04). Each nurse should claim only those hours of credit that he/she actually spend in the educational activity. In accordance with the Standards of the Accreditation Council for Continuing Medical Education (ACCME) and the guidelines of the Association of American Medical Colleges (AAMC), it is the policy of the University of Massachusetts Medical School to disclose whatever interest or affiliation a speaker might have with any commercial organization whose products or services are related to the subject matter being presented. Such disclosure will be made available on the day of the program. This program was supported through educational grants from the following companies: Abbott Laboratories, Inc., Bristol-Myers Squibb, Centocor, Genentech, Pfizer, Procter and Gamble, Smith & Nephew, TAP Pharmaceuticals.